Octarine Bio

Actual: Mar 1, 2020

Foundational paper published in Metabolic Engineering: "Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives." Demonstrated 627±140 mg/L psilocybin production from glucose via engineered yeast.

Why it matters: Proved fermentation-based psilocybin production is viable at pharmaceutical scale. 1,000x claimed cost advantage over mushroom extraction. Also demonstrated production of psilocin, norbaeocystin, baeocystin, and aeruginascin — a full tryptamine toolkit.

Actual: Nov 1, 2020

$1.8M seed round closed. Led by Vaekstfonden (Danish State Growth Fund) with Enexis AB, Oskare Capital, and Bruce Linton. Extended by $1.2M in H1 2021 (total $3.2M seed).

Why it matters: Bruce Linton (Canopy Growth co-founder) involvement signalled cross-pollination between cannabis and psychedelic biotech. Vaekstfonden backing validated Danish synbio ecosystem.

Actual: Sep 1, 2021

Clinical development partnership announced with Clerkenwell Health (UK psychedelic CRO) to bring biosynthetic psilocybin to patients via MHRA pathway. SAB expanded with psychopharmacology expertise (Prof. Jo Neill, Manchester).

Why it matters: Partnership was intended to fast-track from fermentation platform to human clinical trials. However, no trials, dosing, or regulatory submissions ever materialised. Partnership appears dormant as of 2022+.

Actual: May 1, 2023

Strategic pivot to sustainable pigments (PurePalette). Ginkgo Bioworks partnership announced for bio-based dyes using the same fermentation platform. All subsequent fundraising (EUR 4.35M Nov 2023, EUR 12.8M Series A Jan 2026) directed to pigments, not psychedelics.

Why it matters: Marks effective end of psychedelic drug development programme. The fermentation technology proved commercially viable but found a more immediate market in sustainable textiles rather than pharmaceutical development. Psychedelic IP remains but is not being actively developed.